Afrezza (MNKD) - מקדם חוב לטווח ארוך להון

The price history of MannKind Corporation (MNKD) reflects the dynamics of a company whose success is based on owning a unique powder inhalation system for diabetics and protected patents. The current figure is 0.00. The business relies on the high cost of its solutions due to the lack of alternatives to injections, while operational efficiency is enhanced by outsourcing logistics and trials to external contractors.

The selection of defensive assets is based on minimal debt load, which is critical for MannKind Corporation (MNKD) during its expansion into the growing inhalation diabetes therapy segment. The long-term debt-to-equity ratio measures the proportion of loans with a maturity of over one year within the capital structure, allowing investors to assess balance sheet stability and the company's ability to fund growth without the risk of default.